Last reviewed · How we verify

Disease caused by Severe acute respiratory syndrome coronavirus 2 — Treatment Landscape & Competitive Intelligence

Disease caused by Severe acute respiratory syndrome coronavirus 2 (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disease caused by Severe acute respiratory syndrome coronavirus 2, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Veklury remdesivir Gilead Sciences Nucleotide analog RNA polymerase inhibitor SARS-CoV-2 RNA polymerase 2020-01-01
Veklury Veklury ANRS, Emerging Infectious Diseases Nucleoside analog prodrug NS5, Replicase polyprotein 1ab
Xocova ENSITRELVIR Shionogi & Co., Ltd.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. ANRS, Emerging Infectious Diseases · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2
  2. Gilead Sciences · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2
  3. Shionogi & Co., Ltd. · 1 drug in Disease caused by Severe acute respiratory syndrome coronavirus 2

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disease caused by Severe acute respiratory syndrome coronavirus 2:

Cite this brief

Drug Landscape (2026). Disease caused by Severe acute respiratory syndrome coronavirus 2 — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disease-caused-by-severe-acute-respiratory-syndrome-coronavirus-2. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing